Inhibition of ERRα Suppresses Epithelial Mesenchymal Transition of Triple Negative Breast Cancer Cells by Directly Targeting Fibronectin
Overview
Authors
Affiliations
Triple-negative breast cancer (TNBC) patients have poor prognosis due to the aggressive metastatic behaviors. Our study reveals that expression of estrogen related receptor α (ERRα) is significantly (p < 0.01) positively associated with high grade tumors and lymph node metastasis, while negatively correlated with overall survival (OS), in 138 TNBC patients. Targeted inhibition of ERRα by its inverse agonist XCT-790 or si-RNA obviously inhibits in vitro motility of TNBC cells. While over expression of ERRα triggers the invasion and migration of TNBC cells. Further, si-ERRα and XCT-790 inhibit the epithelial mesenchymal transition (EMT) of TNBC cells with increasing the expression of E-cadherin and decreasing fibronectin (FN) and vimentin. While XCT-790 has no effect on the expression of EMT related transcription factors such as Snail or Slug. Further, inhibitors of MAPK, PI3K/Akt, NF-κB signal molecules, which are activated by XCT-790, can not attenuate the suppression effects of XCT-790 on EMT. Alternatively, luciferase reporter gene assays and ChIP analysis indicate that ERRα can directly bind with FN promoter at ERR response element-3 (ERRE-1), ERRE-3, and ERRE-4, while XCT-790 reduces this bond. In vivo data show that ERRα expression is significantly (p < 0.05) correlated with FN in clinical TNBC patients. In MDA-MB-231 tumor xenograft models, XCT-790 decreases the expression of FN, inhibits the growth and lung metastasis, and suppresses the EMT. Our results demonstrate that ERRα functions as a metastasis stimulator and its targeted inhibition may be a new therapeutic strategy for TNBC treatment.
Factors Determining Epithelial-Mesenchymal Transition in Cancer Progression.
Tomecka P, Kunachowicz D, Gorczynska J, Gebuza M, Kuznicki J, Skinderowicz K Int J Mol Sci. 2024; 25(16).
PMID: 39201656 PMC: 11354349. DOI: 10.3390/ijms25168972.
Muduli K, Pradhan J, Prusty M, Samal A, Reddy K, Elangovan S Med Oncol. 2024; 41(3):78.
PMID: 38393411 DOI: 10.1007/s12032-024-02329-1.
ERRα: unraveling its role as a key player in cell migration.
Vanacker J, Forcet C Oncogene. 2023; 43(6):379-387.
PMID: 38129506 DOI: 10.1038/s41388-023-02899-w.
Association of Irisin/FNDC5 with ERRα and PGC-1α Expression in NSCLC.
Nowinska K, Jablonska K, Ciesielska U, Piotrowska A, Haczkiewicz-Lesniak K, Pawelczyk K Int J Mol Sci. 2022; 23(22).
PMID: 36430689 PMC: 9694131. DOI: 10.3390/ijms232214204.
Rewiring of the Endocrine Network in Triple-Negative Breast Cancer.
Li K, Zong D, Sun J, Chen D, Ma M, Jia L Front Oncol. 2022; 12:830894.
PMID: 35847875 PMC: 9280148. DOI: 10.3389/fonc.2022.830894.